News Quantified

STRO – sutro biopharma, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Sutro Biopharma Announces 1-for-10 Reverse Stock Split [Yahoo! Finance]

Sutro Biopharma Announces 1-for-10 Reverse Stock Split

Sutro Biopharma (NASDAQ:STRO) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day [Yahoo! Finance]

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

-10.0%

MISS

Form 8-K SUTRO BIOPHARMA, INC. For: Dec 01

Form 10-Q SUTRO BIOPHARMA, INC. For: Sep 30

Form 8-K SUTRO BIOPHARMA, INC. For: Nov 06

Form SCHEDULE 13G SUTRO BIOPHARMA, INC. Filed by: Affinity Asset Advisors, LLC

Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: Gerber Hans-Peter

Top News Gainers

3/24 Sutro Biopharma Inc (NASDAQ: STRO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 17.6%

3/16 Form S-8 SUTRO BIOPHARMA, INC. 17.4%

3/19 Sutro Biopharma Inc (NASDAQ: STRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. 16.8%

1/31 Form 4 SUTRO BIOPHARMA, INC. For: Jan 29 Filed by: ALBINI EDWARD C 15.5%

10/21 Sutro Biopharma Inc (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. 9.8%

9/5 Sutro Biopharma Inc (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $16.00 price target on the stock. 7.7%

4/20 Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate 7.4%

6/18 Sutro Biopharma to Present at the JMP Securities Life Sciences Conference 6.9%

3/4 Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London 6.2%

10/4 Form S-3 SUTRO BIOPHARMA, INC. 5.9%

Top News Decliners

3/16 Sutro Biopharma Inc (NASDAQ: STRO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -39.3%

4/24 Form DEF 14A SUTRO BIOPHARMA, INC. For: Jun 05 -16.5%

10/7 Sutro Bio up 22% after mixed shelf filing [Seeking Alpha] -12.6%

3/10 Sutro Biopharma Inc (NASDAQ: STRO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -10.4%

2/27 Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference -8.3%

5/14 Q1/2019 3/31/2019 EPS -0.620 ZacksConsensus N/A ActVsEst N/A - N/A -7.7%

8/14 Q2/2019 6/30/2019 EPS -0.600 ZacksConsensus N/A ActVsEst N/A - N/A -7.0%

9/30 Form 4 SUTRO BIOPHARMA, INC. For: Sep 26 Filed by: ALBINI EDWARD C -4.4%

3/12 Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck -3.9%

1/8 Sutro Biopharma Appoints James Panek to Board of Directors -3.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day